Mucosal kinase activity and inflammatory profiles in inflammatory bowel disease, and in relation to tofacitinib response
Mucosal kinase activity profiles are associated with inflammation in IBD, with distinct differences between UC and CD. Baseline kinase activity appears to predict response to tofacitinib, with a marked reduction in kinase activity observed after 8 weeks of treatment in responders. These findings highlight the potential of kinase activity profiling in optimizing therapeutic strategies for IBD.
Authors
- Elly van Koolwijk
- Lisanne Lutter (ORCID: https://orcid.org/0000-0002-1719-2147)
- Sara van Gennep (ORCID: https://orcid.org/0000-0002-9843-0134)
- Bas Oldenburg (ORCID: https://orcid.org/0000-0002-3962-6831)
- Femke van Wijk (ORCID: https://orcid.org/0000-0001-8343-1356)
- Savithri Rangarajan (ORCID: https://orcid.org/0000-0003-2586-8992)
- B. Malvar Fernández
- Geert D’Haens (ORCID: https://orcid.org/0000-0003-2784-4046)
- Carmen S. Horjus Talabur Horje
- Eelco C. Brand (ORCID: https://orcid.org/0000-0002-5195-0562)
- Kris A. Reedquist
- Britt Roosenboom (ORCID: https://orcid.org/0000-0001-7249-6840)
- Ellen G. van Lochem
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Galicia Sur Biomedical Foundation (ES)
- Amsterdam Neuroscience (NL)
- PamGene (Netherlands) (NL)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-09-20
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf174
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Universitair Medisch Centrum Utrecht
- LEO Pharma